Oncology Business Management

Oncology practices are facing a new deadline. When October 1 arrives, they will have to start coding with greater specificity and also get used to many new codes that CMS is going to activate.

New Mexico Cancer Center has a proud record of innovation—its managing partner helped create the Community Oncology Medical Home model in 2012—but the Albuquerque-based practice has still spent much of the past five years fighting to maintain its independence.

The FDA has granted an accelerated approval to pembrolizumab as a treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma following progression on a platinum-based chemotherapy.

The FDA has granted a breakthrough therapy designation to the CDK4/6 inhibitor ribociclib in combination with letrozole for its potential as a frontline therapy for patients with HR-positive, HER2-negative advanced breast cancer.

Blase Polite, MD, discusses the ramifications of CMS Acting Administrator Andy Slavitt's remarks and lingering concerns about MACRA.

CMS, through the Center for Medicare & Medicaid Innovation, has launched an initiative called the Oncology Care Model that is designed to maintain clinical outcomes and reduce the total cost of care. The obvious first question is, has it been designed to do so?

The FDA granted daratumumab (Darzalex) a breakthrough therapy designation for use in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone as a treatment for patients with multiple myeloma following at least 1 prior therapy.